Neurizon Therapeutics Limited has released a press release.
Equity Raising Presentation
Filed with ASX ·
6ix hasn’t read this filing yet.
Neurizon Therapeutics Limited on 6ix
In the deck
Earlier from Neurizon Therapeutics
- Trading Halt
- FDA Clears NUZ-001 for Entry into HEALEY ALS Platform Trial
- Neurizon Completes GMP Tablet Registration Batches
- Elanco executive appointed as Neurizon's Board Observer
- Neurizon to present Q1 FY2026 Results
Later from Neurizon Therapeutics
- New Funding Secured for HEALEY ALS Platform Trial
- Regulatory and Development Update
- Global Trademark Protection Secured Across Key Markets
- Neurizon Completes Entitlement Offer
- Neurizon secures $6million R&D Tax Incentive Rebate
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics